Iswiidhan waxaa la filayaa inay soo jiidan doonto laba jeer oo ka badan maal-gelinta khatarta leh sannadkan
Published
Iswiidhan waxay heli kartaa maal-gelin khatar leh oo qiyaastii 58 bilyan kroon inta lagu jiro 2026. Taas waxaa muujinaya qiyaasaha cusub ee lagu sharaxay maqaal uu qoray Marcus Oscarsson. Maal-gelinta khatarta leh waa lacagta ay maal-geliyayaashu siiyaan shirkado cusub oo si degdeg ah u koraya, inta badan shirkadaha tiknoolajiyada, iyagoo rajaynaya in shirkadahaas ay mustaqbalka aad u faa'iido kaso.
Marka la barbardhigo 2025, wadarta waxay ku dhowaad laba jeer ka weyn tahay. Kordhintan ayaa Iswiidhan ka dhigaysa mid si gaar ah uga muuqda Yurub. Warbixinta ayaa sheegaysa in tirooyinku muujin karaan in jawiga ganacsiga ee Iswiidhan uu soo jiidanayo maal-geliyayaasha caalamka. Si kastaba ha ahaatee, weli lama hubo inta lacagta ah ee dhab ahaan sannadkaas lagu maal-galin doono.
Aasaasaha Atomico, oo ah shirkad maal-gelin Ingiriis ah oo raacda maal-gelinta khatarta leh ee Yurub, ayaa ka hadlaya horumarkan maqaalka. Sida ku xusan cinwaanka maqaalka, waddamada kale ee Yurub ayaa sidoo kale lagu boorinayaa inay raacaan horumarka Iswiidhan. Si kastaba ha ahaatee, qoraalku ma laha sharraxaad dheeraad ah oo ku saabsan tallaabooyinka loo baahan yahay.
Akhristayaasha Iswiidhan, horumarkani waa muhiim sababtoo ah maal-gelinta khatarta leh inta badan waxay saamaysaa tirada shaqooyinka cusub iyo shirkadaha la abuuro. Haddii saadaaliintu saxan yihiin, aduunka shirkadaha cusub ee Iswiidhan ayaa laga yaabaa inay koraan sannadaha soo socda. Weli waa wax hore in la sheego in saadaalintu dhab noqon doonto, sababtoo ah maal-gelinta ayaa si degdeg ah isu beddeli karta marka dhaqaaluhu isbedelo.
Sources: Marcus Oscarsson
More Sweden news
- Slow start for Sverige-id: authorities can get up to nine months' exemption
- Marcus Bergman leaves Sweden after more than 400 matches in Hockeyallsvenskan
- Trust in Sweden could affect the country's defence capability
- Danish drugmaker LEO Pharma postpones its stock market listing
- New rabies vaccine from Sanofi approved in the EU
- This is what the Swedish royals are really like, according to an expert
- Musikhjälpen 2026: The first prize is tickets to a Premier League match
- Business leaders impatient with AI: small progress is no longer enough